Enveric Biosciences
ENVB
11 hedge funds and large institutions have $87.7K invested in Enveric Biosciences in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
38% more funds holding
Funds holding: 8 → 11 (+3)
3.11% more ownership
Funds ownership: 0.93% → 4.05% (+3.1%)
62% less capital invested
Capital invested by funds: $233K → $87.7K (-$145K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
+$14.8K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$11.2K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$20 |
| 4 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$7 |
| 5 |
BlackRock
New York
|
+$7 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$38.3K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$18.2K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$14.5K |
| 4 |
SS
SBI Securities
Tokyo,
Japan
|
-$7 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AI
1
AdvisorShares Investments
Bethesda,
Maryland
| $61.6K | +$7 | +1 | +0% |
|
|
2
UBS Group
Zurich,
Switzerland
| $10.5K | -$38.3K | -5,883 | -67% |
|
|
3
Citigroup
New York
| $8.26K | +$14.8K | +2,276 | New |
|
|
TRCT
4
Tower Research Capital (TRC)
New York
| $6.96K | +$11.2K | +1,715 | +849% |
|
|
5
BlackRock
New York
| $185 | +$7 | +1 | +2% |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| $178 | -$7 | -1 | -2% |
|
|
7
Bank of America
Charlotte,
North Carolina
| $18 | +$20 | +3 | +150% |
|
|
DB
8
Danske Bank
Copenhagen K,
Denmark
| $4 | +$7 | +1 | New |
|
9
Group One Trading
Chicago,
Illinois
| $4 | +$7 | +1 | New |
|
10
National Bank of Canada
Montreal,
Quebec, Canada
| $4 | +$7 | +1 | New |
|
11
Wells Fargo
San Francisco,
California
| $4 | +$7 | +1 | New |
|
|
12
Geode Capital Management
Boston,
Massachusetts
| – | -$18.2K | -2,376 | Closed |
|
|
13
Citadel Advisors
Miami,
Florida
| – | -$14.5K | -1,890 | Closed |
|
ENVB Hedge Fund Activity: Q4 2025 in Review
11 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in Enveric Biosciences (ENVB) for Q4 2025, worth a combined $87.7K — down 62% from $233K a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new ENVB positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 2 trimmed.
The largest buyer was Citigroup, opening a new position worth an estimated $14.8K. The largest seller was UBS Group, cutting an estimated $38.3K.
- 11 institutional investors held Enveric Biosciences (ENVB) as of Q4 2025, up from 8 in Q3 2025.
- Funds reported $87.7K of Enveric Biosciences stock for Q4 2025, down 62% quarter-over-quarter.
- 5 funds opened new Enveric Biosciences positions in Q4 2025 and 2 closed out, a net change of +3 holders.
- The largest Enveric Biosciences buyer in Q4 2025 was Citigroup, an estimated $14.8K added.
- The largest Enveric Biosciences seller in Q4 2025 was UBS Group, an estimated $38.3K sold.
Based on aggregated 13F filings for Q4 2025.